De Luis D A, Romero E, Aller R, Izaola O
University Institute of Endocrinology and Nutrition Hospital Rio Hortega, Valladolid, Spain.
Clin Nutr. 2000 Oct;19(5):367-70. doi: 10.1054/clnu.2000.0127.
The incidence of coronary heart disease (CHD) is greatly increased in overweight diabetic patients. Modification of dietary intake and weight loss improve hypercholesterolaemia. However, cholesterol goal levels are not achieved in several patients under this treatment. The aim of our study was to evaluate the effect of Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, in patients with type 2 diabetes mellitus. A population of 40 diabetic type 2 outpatients were analyzed in a prospective way. The mean+/-SD age was 60.7+/-11.6 years, with a diabetes duration of 8.5+/-6.6 years. All patients were treated with cerivastatin (0.2 mg once a day) for 6 months. Weight HbAlc fasting blood glucose, urine microalbuminuria, total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides were measured at the beginning of the study and again after 3 and 6 months of treatment with cerivastatin. An improvement in lipid levels was achieved, with a significant decrease in LDL-cholesterol (27.7%), total cholesterol (21.4%), triglycerides levels (10.4%) and a significant increase in HDL-cholesterol levels (8.3%) (P<0.05). Cardiovascular risk ratios such as; total cholesterol/HDL-cholesterol and LDL-cholesterol/HDL-cholesterol improved during treatment, decreasing 11.3% and 30%, respectively (P<0.05). Low incidence of side effects was demonstrated. In summary, cerivastatin improved lipid control in patients with type 2 diabetes, with a low incidence of side effects.
超重糖尿病患者的冠心病（CHD）发病率大幅增加。调整饮食摄入和减轻体重可改善高胆固醇血症。然而，接受这种治疗的部分患者并未达到胆固醇目标水平。我们研究的目的是评估3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂西立伐他汀对2型糖尿病患者的疗效。对40名2型糖尿病门诊患者进行了前瞻性分析。平均年龄±标准差为60.7±11.6岁，糖尿病病程为8.5±6.6年。所有患者均接受西立伐他汀治疗（每日0.2毫克），为期6个月。在研究开始时以及使用西立伐他汀治疗3个月和6个月后，分别测量体重、糖化血红蛋白、空腹血糖、尿微量白蛋白、总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇和甘油三酯。血脂水平得到改善，低密度脂蛋白胆固醇显著降低（27.7%），总胆固醇降低（21.4%），甘油三酯水平降低（10.4%），高密度脂蛋白胆固醇水平显著升高（8.3%）（P<0.05）。治疗期间，总胆固醇/高密度脂蛋白胆固醇和低密度脂蛋白胆固醇/高密度脂蛋白胆固醇等心血管风险比有所改善，分别降低了11.3%和30%（P<0.05）。副作用发生率较低。总之，西立伐他汀改善了2型糖尿病患者的血脂控制，且副作用发生率较低。
